{"id":"https://openalex.org/W3031487258","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.2559","title":"Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab.","display_name":"Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab.","publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W3031487258","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.2559","mag":"3031487258"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.2559","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.2559","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.2559","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071489703","display_name":"Nazanin Majd","orcid":"https://orcid.org/0000-0001-6451-544X","observed_orcids":["https://orcid.org/0000-0001-6451-544X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nazanin Majd","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074671045","display_name":"Heather Yan Lin","orcid":"https://orcid.org/0000-0002-1779-7007","observed_orcids":["https://orcid.org/0000-0002-1779-7007"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heather Y. Lin","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019360674","display_name":"Ying Yuan","orcid":"https://orcid.org/0000-0003-3163-480X","observed_orcids":["https://orcid.org/0000-0003-3163-480X","https://orcid.org/0009-0003-4406-2596"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ying Yuan","raw_affiliation_strings":["Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069434459","display_name":"Kristin D. Alfaro-Munoz","orcid":"https://orcid.org/0000-0002-9870-8415","observed_orcids":["https://orcid.org/0000-0002-9870-8415"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristin Alfaro-Munoz","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040657587","display_name":"Kathy Hunter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathy Hunter","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079081497","display_name":"Amy B. Heimberger","orcid":"https://orcid.org/0000-0002-9970-8695","observed_orcids":["https://orcid.org/0000-0002-9970-8695"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy B. Heimberger","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5104124631","display_name":"John Frederick De Groot","orcid":"https://orcid.org/0000-0003-1454-6461","observed_orcids":["https://orcid.org/0000-0003-1454-6461"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Frederick De Groot","raw_affiliation_strings":["The University of Texas, MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas, MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"2559","last_page":"2559"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9121000170707703,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9121000170707703,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.08640000224113464,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.8759999871253967},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.8859999775886536},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.921999990940094},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.9570000171661377},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.8569999933242798},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.9879999756813049},{"id":"https://openalex.org/keywords/treatment-response-biomarkers","display_name":"treatment response biomarkers","score":0.7089999914169312},{"id":"https://openalex.org/keywords/neoadjuvant-immunotherapy","display_name":"neoadjuvant immunotherapy","score":0.8730000257492065},{"id":"https://openalex.org/keywords/recurrent-glioblastoma","display_name":"recurrent glioblastoma","score":0.8840000033378601},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.8109999895095825},{"id":"https://openalex.org/keywords/cd68-macrophages","display_name":"CD68+ macrophages","score":0.9300000071525574},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7120000123977661},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9449999928474426},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.3790000081062317}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8861919641494751},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.808652400970459},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6530992388725281},{"id":"https://openalex.org/C2778326572","wikidata":"https://www.wikidata.org/wiki/Q7852668","display_name":"Tumor-infiltrating lymphocytes","level":4,"score":0.6457715630531311},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6383079290390015},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5645146369934082},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.422461599111557},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4164695739746094},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3337693214416504},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.31350862979888916},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3074635863304138}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.2559","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.2559","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.2559","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307776","display_name":"Merck","ror":"https://ror.org/02891sr49"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3139350874","https://openalex.org/W2996809166","https://openalex.org/W2891636281","https://openalex.org/W2899884840","https://openalex.org/W2911752971","https://openalex.org/W2983207864","https://openalex.org/W6981440505","https://openalex.org/W2936342011","https://openalex.org/W3111805621","https://openalex.org/W2900030764"],"abstract_inverted_index":{"2559":[0],"Background:":[1],"Neoadjuvant":[2],"pembrolizumab":[3,71,285],"improved":[4],"outcome":[5,63],"of":[6,38,43,45,57,64,69,85,94,113,140,145,174,288,314,333],"patients":[7,25,74],"with":[8,26,75,131,162,258,284],"recurrent":[9,30,76],"Glioblastoma":[10],"(GBM)":[11],"in":[12,24,72,88,118,121,319,324],"two":[13],"early":[14],"phase":[15,21],"clinical":[16,55,67],"trials.":[17],"However,":[18],"several":[19],"large":[20],"II/III":[22],"studies":[23],"newly":[27],"diagnosed":[28],"and":[29,53,83,108,127,148,159,182,198,231,330,336],"GBM":[31,89,277],"failed":[32],"to":[33,115,171,192,291,301,316],"demonstrate":[34],"a":[35,253,259,312],"therapeutic":[36],"benefit":[37],"anti-PD-1":[39,58,95,116],"therapy.":[40,59],"Therefore,":[41],"identification":[42],"biomarkers":[44,112],"response":[46,114,315],"is":[47,296,339],"crucial":[48],"for":[49],"appropriate":[50],"patient":[51],"selection":[52],"further":[54],"development":[56],"We":[60,134],"reported":[61],"the":[62,99,141,217,227,292,334],"our":[65],"window-of-opportunity":[66],"trial":[68,342],"neoadjuvant":[70],"15":[73],"GBM,":[77,320],"demonstrating":[78],"rare":[79],"CD8+":[80],"T":[81,281,289],"cells":[82,290],"abundant":[84,280],"CD68+":[86],"macrophages":[87],"tissue":[90,126,278],"after":[91],"3":[92,250,264],"weeks":[93],"treatment":[96,283],"(NCT02337686).":[97],"In":[98],"current":[100],"study,":[101],"we":[102],"compared":[103],"tumor":[104,125,293],"infiltrating":[105],"lymphocyte":[106],"(TIL)":[107],"PD-L1":[109,149,175,233,245,260,308],"scores,":[110],"known":[111],"therapy":[117,318],"other":[119],"cancers,":[120],"pre-trial":[122,181,218,230,335],"vs.":[123],"on-trial":[124,183,208,232,244,337],"associated":[128],"these":[129,161],"markers":[130,197],"survival.":[132,163],"Methods:":[133],"determined":[135],"TIL":[136,178,209,219],"score":[137,151,247,262],"(morphological":[138],"assessment":[139],"presence":[142],"or":[143,177,202],"absence":[144],"TILs,":[146],"0-3)":[147],"H":[150,176,246,261],"(defined":[152],"as":[153],"[1*1+":[154],"%]+[2*2+":[155],"%]+[3*3+":[156],"%],":[157],"0-200)":[158],"correlated":[160],"The":[164,185,207],"Wilcoxon":[165],"signed":[166],"rank":[167],"test":[168],"was":[169,213,235,248],"used":[170,191],"compare":[172],"levels":[173,234],"scores":[179],"between":[180,195,229],"specimens.":[184],"Cox":[186],"proportional":[187],"hazards":[188],"models":[189],"were":[190],"assess":[193],"associations":[194],"correlative":[196],"progression":[199],"free":[200],"survival":[201,204],"overall":[203],"(OS).":[205],"Results:":[206],"level":[210,220],"(median:":[211,221],"3)":[212],"significantly":[214],"higher":[215],"than":[216,256],"1)":[222],"(p":[223,239,272],"=":[224,268,273],"0.031).":[225],"However":[226],"difference":[228],"not":[236,299],"statistically":[237],"significant":[238],">":[240],"0.9).":[241],"Patients":[242],"whose":[243],"\u2265":[249],"trended":[251],"toward":[252],"longer":[254],"OS":[255],"those":[257],"<":[263],"(HR":[265],"[95%":[266],"CI]":[267],"0.225":[269],"[0.043,":[270],"1.183])":[271],"0.0782).":[274],"Conclusions:":[275],"Although":[276],"lacks":[279],"cells,":[282],"increases":[286],"trafficking":[287],"microenvironment,":[294],"which":[295,321],"necessary":[297],"but":[298],"sufficient":[300],"induce":[302],"an":[303],"effector":[304],"T-cell":[305],"response.":[306],"Elevated":[307],"expression":[309],"may":[310],"be":[311],"biomarker":[313],"anti-PD1":[317],"needs":[322],"confirmation":[323],"larger":[325],"studies.":[326],"Further":[327],"genomic,":[328],"transcriptomic,":[329],"methylation":[331],"profiling":[332],"tissues":[338],"ongoing.":[340],"Clinical":[341],"information:":[343],"NCT02337686":[344],".":[345]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-06-05T00:00:00"}